Abstract
Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.
Keywords: Age related macular degeneration, long term, long acting, intravitreal therapy, anti-VEGF agents, pharmacotherapy.
Current Pharmaceutical Design
Title:Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration
Volume: 24 Issue: 41
Author(s): Elad Moisseiev*Anat Loewenstein
Affiliation:
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,Israel
Keywords: Age related macular degeneration, long term, long acting, intravitreal therapy, anti-VEGF agents, pharmacotherapy.
Abstract: Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.
Export Options
About this article
Cite this article as:
Moisseiev Elad*, Loewenstein Anat , Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration, Current Pharmaceutical Design 2018; 24 (41) . https://dx.doi.org/10.2174/1381612825666190123165216
DOI https://dx.doi.org/10.2174/1381612825666190123165216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Chronic Kidney Disease - Different Role for HDL?
Current Medicinal Chemistry Prosodic Impairment in Dementia: Review of the Literature
Current Alzheimer Research A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets
Current Immunology Reviews (Discontinued) L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology Effects of Renin-Angiotensin-Aldosterone System Blockade on Diabetic Patients
Current Enzyme Inhibition Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments
Current Vascular Pharmacology Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Editorial [Hot Topic: The Extracellular Matrix in Health and Disease(Executive Editor: Johannes A. Eble)]
Current Pharmaceutical Design Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets Peripheral Vascular Disease: The Role of MR- Angiography
Current Medical Imaging